Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients-Reference-Cited by-同舟云学术

Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients

Published:2007 Issue:4 Volume:25 Page:329-342
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Delea Thomas E,Sofrygin Oleg,Thomas Simu K,Baladi Jean-Francois,Phatak Pradyumna D,Coates Thomas D

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Reference27 articles.

1. Results of Long-Term Iron-Chelating Therapy

2. Management of Iron Overload in the Pediatric Patient

3. Pharmacosurveillance and quality of care of thalassaemic patients

4. Development of Tridentate Iron Chelators: From Desferrithiocin to ICL670

5. Modeling for Health Care and Other Policy Decisions: Uses, Roles, and Validity

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deferasirox in Patients with Chronic Kidney Disease: Assessing the Potential Benefits and Challenges;Journal of Blood Medicine;2023-11

2. Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study;Haematologica;2023-10-19

3. SAFETY AND EFFICACY OF THALIDOMIDE IN TRANSFUSION-DEPENDENT β-THALASSEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS;Khyber Medical University Journal;2022-09-30

4. Expenditure to Treat Thalassemia- A Major Financial Burden;European Journal of Medical and Health Sciences;2022-09-29

5. A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran;Medicine;2021-10-08